Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 1/20 | 0.68 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.67 |
| ▸ | CTNNB1 | P35222 | 5/20 | 0.66 |
| ▸ | WNT3A | P56704 | 5/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.57 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9048121 | 0.88 | ADAM17 (0.71) | ADAM17GPR84CTNNB1WNT3AALDH1A1 | |
| SCHEMBL4056357 | 0.85 | ADAM17 (0.68) | ADAM17GPR84CTNNB1WNT3AALDH1A1 | |
| SCHEMBL32685253 | 0.85 | ADAM17 (0.68) | ADAM17GPR84CTNNB1WNT3AALDH1A1 | |
| SCHEMBL8557156 | 0.85 | ADAM17 (0.68) | ADAM17GPR84CTNNB1WNT3AALDH1A1 | |
| SCHEMBL28415678 | 0.84 | ADAM17 (0.62) | ADAM17GPR84CTNNB1WNT3AALDH1A1 | |
| SCHEMBL4852469 | 0.84 | ADAM17 (0.66) | ADAM17GPR84CTNNB1WNT3AALDH1A1 | |
| SCHEMBL31295276 | 0.84 | ADAM17 (0.66) | ADAM17GPR84CTNNB1WNT3AALDH1A1 | |
| SCHEMBL1903034 | 0.84 | ADAM17 (0.66) | ADAM17GPR84CTNNB1WNT3AALDH1A1 | |
| SCHEMBL7007977 | 0.84 | ADAM17 (0.66) | ADAM17GPR84CTNNB1WNT3AALDH1A1 | |
| SCHEMBL29722237 | 0.84 | ADAM17 (0.66) | ADAM17GPR84CTNNB1WNT3AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| US-20250171518-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CITY OF HOPE | 2025-05-29 | — | — | US | claimed |
| US-20240316012-A1 | METHODS FOR TREATING LYMPHOMA | NORTHWESTERN UNIVERSITY (US) | 2024-09-26 | — | — | US | claimed |
| US-20240219403-A1 | METHODS FOR INHIBITING KRAS ONCOPROTEIN THROUGH ENHANCED GTPASE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-04 | — | — | US | claimed |
| CN-116390760-A | Compositions and methods for increasing sensitivity of cancer cells to alternating electric fields | 诺沃库勒有限责任公司 | 2023-07-04 | — | — | CN | claimed |
| WO-2022217073-A1 | METHODS FOR INHIBITING KRAS ONCOPROTEIN THROUGH ENHANCED GTPASE ACTIVITY | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-10-13 | — | — | WO | claimed |
| WO-2022093770-A1 | COMBINATION THERAPY WITH PI3K-AKT-MTOR INHIBITORS AND FERROPTOSIS INDUCING AGENTS TO TREAT CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-05-05 | — | — | WO | claimed |
| US-20210102165-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-04-08 | — | — | US | claimed |
| US-20180320133-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-11-08 | — | — | US | claimed |
| EP-3370743-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | City of Hope (US) | 2018-09-12 | — | — | EP | claimed |
| WO-2017079528-A9 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CITY OF HOPE (US) | 2017-06-15 | — | — | WO | claimed |
| WO-2017079528-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CITY OF HOPE (US) | 2017-05-11 | — | — | WO | claimed |
| WO-2013028866-A1 | THERAPEUTIC COMPOUNDS AND METHODS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2013-02-28 | — | — | WO | claimed |
| EP-4729067-A2 | ELECTRODE ASSEMBLY FOR APPLYING TUMOR TREATING FIELDS WITH A SHEET OF ANISOTROPIC MATERIAL | Novocure GmbH (CH) | 2026-04-22 | — | — | EP | disclosed |
| EP-4638441-A1 | GLYCINE DERIVATIVES WITH P2X4 RECEPTOR-BLOCKING ACTIVITY AS DIAGNOSTICS AND FOR THE TREATMENT OF PAIN, INFLAMMATION, CANCER, AND OTHER P2X4 RECEPTOR-RELATED DISEASES | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2025-10-29 | — | — | EP | disclosed |
| US-12415844-B2 | BCMA specific VCAR compositions and methods for use | POSEIDA THERAPEUTICS, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-4866084-A | EXTRACTED FROM SPONGES | HARBOR BRANCH OCEANOGRAPHIC INSTITUTION, INC. (US) | 1989-09-12 | — | — | US | disclosed |
| EP-0259085-A1 | 2-Guanidino-4-arylthiazoles for treatment of peptic ulcers | PFIZER INC. (US) | 1988-03-09 | — | — | EP | disclosed |
| US-4631280-A | Pyridazine derivatives having a psychotropic action, and medicaments in which they are present | SANOFI (FR) | 1986-12-23 | — | — | US | disclosed |
| US-4565814-A | Pyridazine derivatives having a psychotropic action and compositions | SANOFI (FR) | 1986-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180320133-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CD4, ICOS, CD2 | ADAM17 1660/4885GPR84 626/4885CTNNB1 1701/4885 |
| US-20250171518-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CD4, ICOS, CD2 | ADAM17 1660/4885GPR84 626/4885CTNNB1 1701/4885 |
| US-20210102165-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CD4, ICOS, CD2 | ADAM17 1660/4885GPR84 626/4885CTNNB1 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.